Gujarat Themis Biosyn Ltd logo

Gujarat Themis Biosyn Ltd

GUJTHEM NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹3,764 Cr
Volatility
Moderate
P/E Ratio
78.02
EBITDA
₹75.53 Cr
Return on Equity
19.64%
Debt to Equity
0.56
Book Value
₹0.67
52W High
₹479
52W Low
₹225.05

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Gujarat Themis Biosyn Ltd insights

54 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.1%

Weaknesses

4
  • Stock is trading at 13.2 times its book value
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 89.3 to 134 days.
  • Promoter holding has decreased over last 3 years: -4.13%

Growth Rate

Revenue Growth
8.73% ↗
Net Income Growth
5.12% ↗
Cash Flow Change
41.77% ↗
ROE
-33.15% ↘
ROCE
-39.54% ↘
EBITDA Margin (Avg.)
-3.98% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 39d ago
AI opinion · based on fundamentals
Risk high

Gujarat Themis Biosyn Ltd is a healthcare company with a market cap of ₹4,214 Cr trading at a PE of 90.3x and 14.6x book value. The company has delivered strong long-term stock CAGR of 48% over 10 years but recent profit growth has turned negative at -4% TTM, while ROE has moderated from a 5-year average of 29% to 17% in the last year.

Bull Case 7
  • Strong long-term wealth creation with stock CAGR of 48% over 10 years and 55% over 5 years
  • Robust long-term ROE track record of 32% over 10 years and 29% over 5 years, indicating efficient capital deployment
  • Compounded sales growth of 18% over 10 years demonstrates sustained revenue expansion
  • Compounded profit growth of 26% over 10 years reflects strong long-term earnings trajectory
  • TTM sales growth of 10% shows continued top-line momentum despite profit pressures
  • 5-year compounded profit growth of 9% remains positive despite recent deceleration
  • 3-year ROE of 23.1% remains well above cost of equity for most Indian companies
Bear Case 8
  • PE ratio of 90.3x is extremely elevated relative to healthcare sector averages, leaving little margin of safety
  • TTM profit growth has turned negative at -4%, signaling earnings deterioration
  • 3-year compounded profit decline of -7% indicates a sustained earnings downtrend
  • Price-to-book of 14.6x is very high, implying significant premium to asset value
  • Debtor days have increased from 89.3 to 134 days, suggesting deteriorating working capital efficiency and potential collection issues
  • Promoter holding has decreased by 4.13% over the last 3 years, which may signal reduced insider confidence
  • ROE has declined sharply from 29% (5-year average) to 17% in the last year, a 12 percentage point drop
  • Company might be capitalizing interest costs, which could overstate reported profits and asset values

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 39d ago
Headwinds 2
  • Arbitration claim filed Jun 26

    Gujarat Themis Biosyn initiated arbitration against Optimus Drugs claiming ₹90.38 crore for breach of supply agreement, indicating a disrupted supplier relationship.

  • Indirect share encumbrance disclosed Jul 2

    CTL Trusteeship disclosed an indirect encumbrance over Gujarat Themis Biosyn shares due to pledges by Vividhmargi Investments, signaling promoter-level leverage risk.

Positives 3
  • Acquisitions fuel growth strategy Jun 29

    Company reported FY26 revenue of ₹16,582.28 lakh and announced acquisitions of MicroBiopharm Japan and Sanofi's select product portfolio to expand capabilities.

  • Ireland subsidiary incorporated Jun 17

    Step-down subsidiary Themis Biosyn Private Limited incorporated in Ireland on June 16, 2026, with €100 share capital, signaling international expansion intent.

  • Board evaluating fund raising Jun 16

    Board meeting scheduled for June 19, 2026 to evaluate raising funds via preferential issue and private placement of equity shares and debentures.

Neutral 1
  • Promoter inter-se share transfer Jun 24

    Sachin D. Patel will purchase up to 26 lakh shares from Themis Medicare Limited between June 30–July 3, 2026 at ₹400.45 per share, a promoter-level rebalancing.

TL;DR: Gujarat Themis Biosyn is in active expansion mode with two acquisitions (MicroBiopharm Japan, Sanofi portfolio), international subsidiary setup in Ireland, and potential fundraising underway. Key risks include a ₹90.38 crore arbitration dispute with a supplier and indirect encumbrance on promoter shares. The growth trajectory is improving with strategic moves into new geographies and product portfolios, though execution and funding clarity remain near-term watchpoints.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
50
40
39
42
39
35
40
38
36
42
43
44
44
Expenses
26
23
21
21
20
19
21
22
22
21
22
25
23
Operating Profit
24
17
18
21
19
15
19
16
14
21
21
19
21
OPM %
47%
42%
46%
50%
48%
44%
48%
42%
39%
49%
49%
44%
48%
Other Income
1
1
1
1
1
0
0
1
0
1
0
1
0
Interest
0
0
0
0
0
0
0
0
0
0
1
2
2
Depreciation
1
1
1
1
1
1
2
1
2
3
4
4
4
PBT
24
17
18
21
18
14
17
16
12
19
17
14
15
Tax %
26%
26%
26%
24%
26%
26%
25%
25%
25%
24%
26%
24%
27%
Net Profit
18
13
13
16
13
11
13
12
9
14
12
11
11
EPS in Rs
1.63
1.15
1.19
1.46
1.21
0.97
1.19
1.1
0.83
1.31
1.14
1
1.02
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
31
33
36
39
41
85
91
115
148
170
151
166
174
Expenses
25
27
30
33
34
53
50
57
75
91
81
90
91
Operating Profit
7
6
6
6
7
32
40
58
74
79
70
76
82
OPM %
21%
19%
17%
16%
18%
37%
45%
51%
50%
46%
46%
46%
47%
Other Income
0
0
0
0
2
2
3
4
7
4
2
2
2
Interest
0
0
0
0
0
1
1
1
0
0
0
3
5
Depreciation
1
1
1
1
1
1
2
2
3
4
5
13
15
PBT
5
5
5
5
8
31
41
59
77
79
66
62
65
Tax %
0%
0%
10%
20%
22%
24%
26%
26%
25%
25%
26%
25%
—
Net Profit
5
5
4
4
6
24
30
44
58
59
49
47
49
EPS in Rs
0.42
0.42
0.4
0.36
0.59
2.17
2.77
4
5.32
5.43
4.48
4.28
4.47
Div. Payout %
0%
0%
0%
0%
0%
10%
0%
37%
14%
12%
15%
16%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
7
7
7
7
7
7
7
7
7
7
11
11
Reserves
-8
-3
1
5
11
35
63
96
142
194
237
277
Borrowings
6
3
4
1
6
8
5
1
0
3
30
162
Other Liabilities
9
8
9
8
8
14
14
18
17
17
22
54
Total Liabilities
15
15
21
20
33
64
88
122
166
221
301
503
Fixed Assets
10
9
11
11
15
17
19
19
33
38
41
289
CWIP
0
0
0
0
1
0
2
13
21
91
184
121
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
5
5
11
10
17
47
67
90
113
92
76
93
Total Assets
15
15
21
20
33
64
88
122
166
221
301
503
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
3
4
3
6
1
1
11
40
39
64
91
49
Investing
0
-1
-3
-1
-6
-3
-2
-30
-20
-55
-112
-172
Financing
-3
-3
0
-4
5
2
-5
-14
-13
-9
26
115
Net Cash Flow
-1
0
0
1
0
0
3
-4
6
0
5
-9
Free Cash Flow
2
3
0
5
-5
-3
7
26
16
-10
-25
-124
CFO/OP
44
73
57
99
25
24
51
94
81
107
154
79
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28
24
71
26
52
87
59
80
44
58
76
134
Inventory Days
—
—
—
78
—
194
144
255
201
33
75
263
Days Payable
—
—
—
947
—
240
84
145
131
99
218
625
Cash Conversion Cycle
28
24
71
-844
52
41
119
189
114
-7
-67
-228
Working Capital Days
-76
-70
-42
-43
-58
42
80
155
91
50
46
8
ROCE %
121%
81%
55%
42%
45%
84%
67%
67%
61%
45%
27%
18%

Shareholding Pattern

As of Jun 2026
Promoters 70.86%
Public 19.46%
Others 6.73%
FIIs 1.77%
DIIs 1.18%
Total 100.00%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Feb 2025Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
74.99%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
70.86%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.00%
1.05%
1.44%
1.49%
1.42%
0.00%
1.91%
2.51%
2.95%
1.96%
1.80%
1.77%
DIIs
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.03%
0.02%
0.03%
0.03%
0.02%
0.82%
1.18%
1.17%
1.17%
1.16%
1.17%
1.17%
1.17%
1.17%
1.18%
1.18%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
22.07%
21.61%
21.89%
21.64%
21.30%
21.41%
21.60%
21.85%
22.09%
22.13%
21.85%
23.40%
22.26%
21.17%
20.44%
20.12%
19.75%
19.66%
19.31%
18.72%
19.90%
19.88%
19.46%
Others
2.90%
3.36%
3.08%
3.34%
3.67%
3.56%
3.38%
3.12%
2.90%
2.84%
3.11%
5.71%
5.00%
5.35%
6.03%
6.42%
8.22%
6.39%
6.14%
6.29%
6.10%
6.28%
6.73%
No. of Shareholders
10,175
10,158
12,930
13,059
13,917
13,830
14,904
16,550
16,804
17,373
19,846
28,655
29,576
30,280
31,271
30,934
30,695
30,673
28,945
28,319
27,325
26,886
27,010

Documents

Frequently Asked Questions about Gujarat Themis Biosyn Ltd

What does Gujarat Themis Biosyn Ltd do?
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]
Where is Gujarat Themis Biosyn Ltd (GUJTHEM) listed?
Gujarat Themis Biosyn Ltd is listed on the Indian stock exchanges. It is listed on NSE: GUJTHEM and BSE: 506879. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Gujarat Themis Biosyn Ltd belong to?
Gujarat Themis Biosyn Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has a market capitalisation of approximately ₹3763.66 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Gujarat Themis Biosyn Ltd?
The Price-to-Earnings (PE) ratio of Gujarat Themis Biosyn Ltd is 78.02. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Gujarat Themis Biosyn Ltd?
Over the past 52 weeks, Gujarat Themis Biosyn Ltd has traded between a low of ₹225.05 and a high of ₹479. This range helps investors understand the stock's price volatility and recent trading levels.
Does Gujarat Themis Biosyn Ltd pay dividends?
Yes, Gujarat Themis Biosyn Ltd has a dividend yield of 0.19%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Gujarat Themis Biosyn Ltd?
Gujarat Themis Biosyn Ltd has a Return on Equity (ROE) of 19.64%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Gujarat Themis Biosyn Ltd on Tapetide?
On Tapetide, you can view Gujarat Themis Biosyn Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process[1]

Website gtbl.in
CEO Dr. Sachin Dinesh Patel CChem., Ph.D.
Employees 221
Listed 2025-02-25
Face Value ₹ 1
Issued Size 10,89,65,265

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List